FDA Improves Drug Review Timeframes, Aims For Original PDUFA Standard

This article was originally published in The Tan Sheet

07 Dec 2009
News

The Tan Sheet

Executive Summary

After an almost two-year hiatus from strict adherence to Prescription Drugs User Fee Act review timeframes, Office of New Drugs Director John Jenkins has told review staff that, once again, they should strive to meet the user fee deadlines

Existing Subscriber? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Subjects
OTC Drugs

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

OTC Drugs

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS103590

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS103590

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

FDA Improves Drug Review Timeframes, Aims For Original PDUFA Standard

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

FDA Improves Drug Review Timeframes, Aims For Original PDUFA Standard

News

Executive Summary

Related Content

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert